Clinical outcomes and risk stratification in unresectable biliary tract cancers undergoing radiation therapy
Authors:
Open Access
- 1 August 2024
- journal article
- research article
- Published by Springer Nature in Radiation Oncology
- Vol. 19 (1) , 1-11
Abstract
Background: Biliary tract cancers (BTC) are rare and aggressive malignancies originating from intrahepatic and extrahepatic bile ducts and the gallbladder. Surgery is the only curative option, but due to late-stage diagnosis, is frequently not feasible, leaving chemotherapy as the primary treatment. Radiotherapy (RT) can be an effective alternative for patients with unresectable, non-metastatic BTC despite the generally poor prognosis and significant variability. To help manage patients with unresectable BTC who receive RT, we aimed to identify prognostic markers that could aid in predicting overall survival (OS). Methods: A retrospective cohort study was conducted at the University of Pennsylvania, involving seventy-eight patients with unresectable BTC treated with definitive intent RT. Comprehensive demographic, clinical, and treatment-related data were extracted from the electronic medical records. Univariate and multivariate Cox regressions were employed to identify predictors of OS after RT. A biomarker model was developed for refined survival prediction. Results: The cohort primarily comprised patients with good performance status without significant hepatic dysfunction at presentation. The predominant treatment approach involved hypofractionated RT or concurrent 5FU-based chemoRT. Median OS after RT was 12.3 months, and 20 patients (15.6%) experienced local progression with a median time of 30.1 months. Univariate and multivariate analyses identified CA19-9 (above median) and higher albumin-bilirubin (ALBI) grades at presentation as significant predictors of poor OS. Median OS after RT was 24 months for patients with no risk factors and 6.3 months for those with both. Conclusions: Our study demonstrates generally poor but significantly heterogeneous OS in patients with unresectable BTC treated with RT. We have developed a biomarker model based on CA19-9 and ALBI grade at presentation that can distinguish sub-populations with markedly diverse prognoses. This model can aid the clinical management of this challenging disease.Keywords
All Related Versions
This publication has 34 references indexed in Scilit:
- The ALBI score: From liver function in patients with HCC to a general measure of liver functionJHEP Reports, 2022
- Prognostic utility of albumin‐bilirubin grade for short‐ and long‐term outcomes following hepatic resection for intrahepatic cholangiocarcinoma: A multi‐institutional analysis of 706 patientsJournal of Surgical Oncology, 2019
- Dose escalation of radiotherapy in unresectable extrahepatic cholangiocarcinomaCancer Medicine, 2018
- A pilot study of concurrent chemoradiotherapy with gemcitabine and cisplatin in patients with locally advanced biliary tract cancerCancer Chemotherapy and Pharmacology, 2016
- Albumin–bilirubin versus Child–Pugh score as a predictor of outcome after liver resection for hepatocellular carcinomaBritish Journal of Surgery, 2016
- Outcomes after Resection of Intrahepatic Cholangiocarcinoma: External Validation and Comparison of Prognostic ModelsJournal of the American College of Surgeons, 2015
- CholangiocarcinomaThe Lancet, 2014
- Risk factors for cholangiocarcinomaHepatology, 2011
- External-beam radiotherapy for localized extrahepatic cholangiocarcinomaInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2006
- Chemoradiation May Prolong Survival of Patients with Non-Bulky Unresectable Extrahepatic Biliary CarcinomaStrahlentherapie und Onkologie, 2004